GlassScriptPhysician profile
Nathan Augustus Starkman
NPI 1730707134
$2,700.39
in general payments reported to CMS, 2019-2025
13 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,025 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.81 | 2024-2025 | |
| Janssen Biotech, INC. | $390.84 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $273.23 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $270.36 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $268.50 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $246.84 | 2024-2025 | Entyvio |
| Boston Scientific Corporation | $140.32 | 2025 | Axios |
| Lilly USA, LLC | $125.00 | 2025 | Omvoh |
| Janssen Pharmaceuticals, INC | $125.00 | 2025 | Invega Sustenna |
| Qol Medical, LLC | $122.19 | 2025 | Sucraid |
| Neurocrine Biosciences, INC. | $118.09 | 2024 | Ingrezza |
| Pfizer INC. | $22.32 | 2024 | |
| Enterra Medical, INC. | $16.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Starkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.